Abstract
8187 Background: Though significant advances have been made in cancer treatment, CINV still remains significant patients (pts) concerns. Antiemetic guidelines based on emesis rate category have been proposed for the prevention of CINV (Support Care Cancer 2002; 10: 519–22). Dexamethasone (Dex) and 5HT3 antagonist are recommended for the prevention of acute and delayed CINV of CT using high emesis category drugs. However, there is no standard recommendation for delayed CINV of moderate emesis category drugs, such as CPT-11. The efficacy of granisetron, 5HT3 antagonist, on delayed CINV after CPT-11 and 5-FU based CT was investigated. Methods: Pts who had a delayed CINV were eligible for the study. Treatment regimen was consisted of a 90-min infusion of CPT-11 150mg/m2 on day 1 and 15, and UFT 375mg/m2/day on days 3–7, 10–14, 17–21 and 24–28, q5w. All pts received intravenous betamethasone and granisetron for prophylaxis against acute emesis on the day of CPT-11 administration. When pts had delayed CINV, 2 mg of granisetron was orally administered on days 2–6, and 16–20 of next treatment cycle. The severity of their gastrointestinal symptoms (anorexia, nausea, vomiting) on days 2–7, and 16–21 was recorded every day according to NCI-CTC, and pts preference of this treatment was recorded using questionnaire on days 8 and 22. The efficacy of the treatment was assessed in each patient by the comparison of severity of CINV with or without oral granisetron. Results: 16 pts (53.3%) of 30 pts who had received the CT had delayed CINV. The incidence of grade 2 or more vomiting was significantly greater in female than in male pts (54.6% vs 32.1%, p=0.002). Although granisetron did not improve the overall incidence of anorexia, nausea, and vomiting, the incidence of grade 2 or more vomiting in female pts was significantly reduced by granisetron (54.6% vs 32.4%, p=0.001). The questionnaire on pts preference revealed 76% of pts had preference for the treatment. Conclusions: Oral administration of granisetron for prevention against delayed CINV might be effective in female pts. No significant financial relationships to disclose.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have